Payment overview · 2025
General Payments
$935.01
51 reported records · 11 companies
Healthcare provider profile · identity verified
Nativel J Collins, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MANTACHIE, MS · NPI 1437162690
Verified facts
What the public records show
CMS Open Payments records show Nativel J Collins, CFNP received $935.01 in general payments during 2025 across 51 reported records.
Novo Nordisk Inc accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 577 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.54 | 21.0% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$138.83 | 14.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.68 | 14.6% | 12 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $134.62 | 14.4% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $97.08 | 10.4% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.54 | 8.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.11 | 6.6% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.97 | 2.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.42 | 2.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $21.04 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.18 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $902.74 | 50 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $138.83 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $134.62 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $104.37 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $97.08 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $95.54 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $95.54 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.42 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.00 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.20 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 208 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 175 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 325 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 577 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
208 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
325 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
577 | 133 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 577 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 420 | 125 |
| Mounjaro | Tirzepatide | 325 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 105 |
| Metformin Hcl Er | Metformin Hcl | 246 | 74 |
| Metformin Hcl | Metformin Hcl | 229 | 77 |
| Farxiga | Dapagliflozin Propanediol | 208 | 48 |
| Lisinopril | Lisinopril | 184 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 52 |
| Jardiance | Empagliflozin | 175 | 43 |
| Novolog Flexpen | Insulin Aspart | 153 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 40 |
| Losartan Potassium | Losartan Potassium | 145 | 40 |
| Ezetimibe | Ezetimibe | 129 | 47 |
| Tresiba Flextouch U-100 | Insulin Degludec | 121 | 43 |
| Glimepiride | Glimepiride | 116 | 36 |
| Gabapentin | Gabapentin | 106 | 33 |
| Tresiba Flextouch U-200 | Insulin Degludec | 93 | 24 |
| Carvedilol | Carvedilol | 88 | 33 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 87 | 23 |
| Fenofibrate | Fenofibrate | 86 | 20 |
| Trulicity | Dulaglutide | 83 | 19 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 82 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 17 |
| Furosemide | Furosemide | 58 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 23 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 54 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 14 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Novolog | Insulin Aspart | 34 | 17 |
| Repaglinide | Repaglinide | 34 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Omnipod 5 Dexg7g6 Intro(Gen 5) | Insulin Pmp Cart,aut,g6/7,cntr | 28 | 28 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Levemir Flexpen | Insulin Detemir | 24 | 14 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Omeprazole | Omeprazole | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $935.01 · 51 records | Novo Nordisk Inc | BREZTRI, CeQur Simplicity, EVENITY, FARXIGA, JARDIANCE, Korlym, MINIMED 780G, MOUNJARO, NEXLETOL, Omnipod, Ozempic, Rybelsus, TWIIST, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error